0.15Open0.15Pre Close0 Volume123 Open Interest25.00Strike Price0.00Turnover155.60%IV42.41%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.0864Delta0.0381Gamma117.73Leverage Ratio-0.0380Theta0.0003Rho10.17Eff Leverage0.0042Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet